Search clinical trials for: MART-1 antigen

Total 16746 results

Genzyme, a Sanofi Company

Unknown

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
European Organisation for Research and Treatment...

Terminated

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Intraocular Melanoma

Belgium, Denmark
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase

Melanoma | Neoplasm Metastasis

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin) | Non-melanomatous Skin Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
Institute of Cancer Research, United Kingdom
Trans Tasman Radiation Oncology Group

Active, not recruiting

Study of Tumour Focused Radiotherapy for Bladder Cancer (RAIDER)

Bladder Cancer

United Kingdom, New Zealand, Australia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | B Acute Lymphoblastic Leukemia

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
University of Miami
University of Miami Sylvester Comprehensive Cancer Center

Withdrawn

Mohs and Immunofluorescence for Malignant Melanoma In Situ

Lentigo Maligna | Melanoma In Situ

United States
Xijing Hospital

Unknown

CD147-CART Cells in Patients With Recurrent Malignant Glioma.

Recurrent Glioblastoma | CD147 Positive

China
National Cancer Institute (NCI)

Completed

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Completed

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Recurrent Melanoma | Stage IV Melanoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Pfizer

Completed

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

Rheumatoid Arthritis | Healthy Volunteers

United States
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Central Hospital, Nancy, France

Not yet recruiting

Evaluation of Antigen-specific T Cells in Patients With Antisynthetase Syndrome and Interstitial Lung Disease (CYTILDASS)

Antisynthetase Syndrome

France
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

B-Cell Acute Lymphoblastic Leukemia

China
Children's Hospital of Philadelphia
Agency for Healthcare Research and Quality (AHRQ)

Completed

Improving Otitis Media Care With Clinical Decision Support (OMHIT)

Otitis Media

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Duke University
National Cancer Institute (NCI)

Terminated

Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer

Pancreatic Cancer

United States
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Penumbra Inc.

Active, not recruiting

Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities (SURF)

Aneurysm, Brain

United States, Germany, Switzerland, Spain, Canada, Italy
UCB Pharma
Parexel

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

Psoriasis

United Kingdom
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
Bukwang Pharmaceutical

Active, not recruiting

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)

Parkinson Disease | Dyskinesias

United States

Search clinical trials for: MART-1 antigen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations